EGFR and lung cancer: Individuals with non‐small cell lung cancer (NSCLC) positive for activating mutations of the epidermal growth factor receptor (EGFR) gene are sensitive to first‐ and second‐generation EGFR–tyrosine kinase inhibitors (TKIs) such as gefitinib, erlotinib, and afatinib.